Document is current

Any future updates will be listed below

Comment on do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years

Crossref DOI link: https://doi.org/10.1007/s00345-025-05875-z

Published Online: 2025-08-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark